Shareholders being diluted. Shares outstanding up 11% from December 2022 to July 2026.
Privia Health had 11% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Privia Health had 11% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Cash flow well above reported profit. Free cash flow is 4.7× reported profit.
Free cash flow is 4.7× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.
Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $817M in 2020 to $2.1B in 2025.
Privia Health's fiscal-year revenue rose in each of the five years to 2025, from $817M to $2.1B.
Fast revenue growth. Revenue grew 24% in the 12 months to June 2026 vs the 12 months before, faster than 82% of peers.
Revenue grew 24% in the 12 months to June 2026 vs the 12 months before, faster than 82% of its peers.
Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 1.04Sector median: 0.2215 · MAD: 0.2039
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Privia Health
Is Privia Health getting weaker?
Its latest SEC filing (Aug 6, 2026) showed no major changes. Its overall score is unchanged at 56/100 since Oct 28, 2026.
How is Privia Health valued vs its peers?
Priced about in line with its peers. Valuation scores 42/100 against 1,393 healthcare peers.
Is Privia Health growing?
Yes, faster than most of its peers. Growth scores 81/100 against 1,393 healthcare peers.Earnings per share growth 82.1% vs a peer median of 9.8% (stronger than 85% of peers).Earnings per share growth 82.1% vs peers 9.8% (stronger than 85% of peers).
How profitable is Privia Health?
About as profitable as its peers. Profitability scores 50/100 against 1,393 healthcare peers.Return on invested capital 9.6% vs a peer median of 4.7% (stronger than 66% of peers).Return on invested capital 9.6% vs peers 4.7% (stronger than 66% of peers).Operating margin 1.9% vs a peer median of 7.1% (weaker than 64% of peers).Operating margin 1.9% vs peers 7.1% (weaker than 64% of peers).
How risky is Privia Health?
Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Debt / equity 0.01× vs a peer median of 0.22× (stronger than 89% of peers).Debt / equity 0.01× vs peers 0.22× (stronger than 89% of peers).Current ratio 1.62× vs a peer median of 2.59× (weaker than 70% of peers).Current ratio 1.62× vs peers 2.59× (weaker than 70% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jun 30, 2026 · filed Aug 6, 2026 · compared with the quarter ended Mar 31, 2026
No major changes
Previous quarter
Latest quarter
Change
Revenue (12 months)
2.2B USD
2.4B USD
+5.0%
Net income (12 months)
21.8M USD
28.1M USD
+29.2%
Operating margin
1.6%
1.9%
+0.3 pts
Cash
419.5M USD
412.2M USD
−1.7%
Shares outstanding
126.0M
127.7M
+1.4%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Health Information Services companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2021
FY 2022
FY 2023
FY 2024
FY 2025
Change
Operating margin
-22.5%
-1.4%
1.2%
1.0%
1.6%
▲ 0.6 pts
Net margin
-19.5%
-0.6%
1.4%
0.8%
1.1%
▲ 0.3 pts
Return on assets (ROA)
-27.4%
-1.1%
2.3%
1.3%
1.7%
▲ 0.4 pts
Return on equity (ROE)
-44.1%
-1.7%
4.1%
2.3%
3.1%
▲ 0.8 pts
Free cash flow margin
5.6%
3.5%
4.9%
—
—
—
Current ratio
2.35×
2.09×
1.81×
1.86×
1.60×
▼ 14%
Debt to equity
0.08×
0.00×
—
—
—
—
Interest coverage
-197.67×
-38.24×
—
—
—
—
PRVA price history
Price history is added with the daily price update and will appear after the next one.